Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Company Overview

Vertex Pharmaceuticals Inc. is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms. Its approved therapies include potentiators and corrector combinations that have expanded treatment options for people with different CFTR mutations. These drugs, introduced progressively since the early 2010s, are the cornerstone of Vertex’s commercial business and have enabled broad access programs and partnerships to reach CF patients globally.

Beyond cystic fibrosis, Vertex has invested heavily in next‑generation technologies and new therapeutic areas. The company is advancing programs in gene editing and cell therapy, including a collaboration with CRISPR Therapeutics to develop gene‑editing treatments for hemoglobinopathies such as sickle cell disease and beta‑thalassemia, and it has pursued stem cell–derived approaches for type 1 diabetes following its acquisition of Semma Therapeutics. Vertex’s pipeline also includes earlier‑stage research across other serious diseases where precision genetic or cell‑based approaches may offer durable benefit.

Vertex maintains a commercial presence in North America, Europe and other international markets while sustaining a large R&D footprint to support discovery and clinical development. The company is led by Chief Executive Officer Reshma Kewalramani and a management team with deep experience in both clinical development and commercial operations. Vertex emphasizes patient access, long‑term innovation and collaboration with academic and industry partners as it seeks to expand its impact beyond cystic fibrosis into additional rare and serious diseases.

Key Stats

• Today's Range: $433.15 to $444.32
• 50-Day Range: $423.24 to $499.17
• 52-Week Range: $362.50 to $507.92
• Volume: 1.22 million shs
• Average Volume: 1.13 million shs
• Market Capitalization: $110.23 billion
• P/E Ratio: 25.76
• Dividend Yield: N/A
• Price Target: $555.17
• Consensus Rating: Moderate Buy

Vertex Pharmaceuticals Stock Analysis - MarketRank™

Vertex Pharmaceuticals scored higher than 91% of companies evaluated by MarketBeat, and ranked 54th out of 851 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 1 strong buy rating, 21 buy ratings, 4 hold ratings, and no sell ratings.

Upside Potential

Vertex Pharmaceuticals has a consensus price target of $555.17, representing about 27.8% upside from its current price of $434.31.

Amount of Analyst Coverage

Vertex Pharmaceuticals has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 12.08%

Earnings Growth

Earnings for Vertex Pharmaceuticals are expected to grow by 12.08% in the coming year, from $16.97 to $19.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vertex Pharmaceuticals is 25.76, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 42.78.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vertex Pharmaceuticals is 25.76, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 17.54.

Price to Earnings Growth Ratio

Vertex Pharmaceuticals has a PEG Ratio of 1.87. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Vertex Pharmaceuticals has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.65% of the float of Vertex Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 4.31.

Change versus previous month

Short interest in Vertex Pharmaceuticals has recently decreased by 3.77%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vertex Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Vertex Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.19

News Sentiment

Vertex Pharmaceuticals has a news sentiment score of 1.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 32 news articles for Vertex Pharmaceuticals this week, compared to 11 articles on an average week.

Search Interest

33 people have searched for VRTX on MarketBeat in the last 30 days. This is an increase of 18% compared to the previous 30 days.

MarketBeat Follows

33 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,402,568.00 in company stock.

Percentage Held by Insiders

0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

Percentage Held by Institutions

90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/04/2026
• Today: 5/19/2026
• RBC Capital Markets Global Healthcare Conference 2026: 5/19/2026
• Bernstein 42nd Annual Strategic Decisions Conference: 5/29/2026
• Next Earnings (Estimated): 8/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VRTX
• CIK: 875320
• Web: www.vrtx.com
• Phone: (617) 341-6100
• Fax: 617-576-2109
• Employees: 6,400
• Year Founded: 1989

Price Target and Rating

• Average Price Target for Vertex Pharmaceuticals: $555.17
• High Price Target: $641.00
• Low Price Target: $436.00
• Potential Upside/Downside: +27.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 26 Analysts

Profitability

• EPS (Trailing Twelve Months): $16.86
• Trailing P/E Ratio: 25.76
• Forward P/E Ratio: 25.59
• P/E Growth: 1.87
• Net Income: $3.95 billion
• Net Margins: 35.51%
• Pretax Margin: 42.28%
• Return on Equity: 23.86%
• Return on Assets: 17.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.02
• Quick Ratio: 2.57

Sales & Book Value

• Annual Sales: $12.00 billion
• Price / Sales: 9.18
• Cash Flow: $17.48 per share
• Price / Cash Flow: 24.84
• Book Value: $76.29 per share
• Price / Book: 5.69

Miscellaneous

• Outstanding Shares: 253,800,000
• Free Float: 253,297,000
• Market Cap: $110.23 billion
• Optionable: Optionable
• Beta: 0.30